Lyle J. Goldstein, Ph.D.
Affiliations: | 2002 | Princeton University, Princeton, NJ |
Area:
International Law and RelationsGoogle:
"Lyle Goldstein"Parents
Sign in to add mentor| Aaron Friedberg | grad student | 2002 | Princeton | |
| (Valleys of vulnerability: Instability in asymmetric nuclear rivalries.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Goldstein LJ, Mansutti M, Levy C, et al. (2021) A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida). Breast Cancer Research and Treatment |
| Gradishar WJ, Moran MS, Abraham J, et al. (2021) NCCN GuidelinesĀ® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network : Jnccn. 19: 484-493 |
| Gradishar WJ, Anderson BO, Abraham J, et al. (2020) Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 452-478 |
| Goldstein LJ, Perez RP, Yardley D, et al. (2020) A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. Breast Cancer Research : Bcr. 22: 4 |
| Lewis B, Meeker CR, Handorf E, et al. (2020) HSR20-093: Psychosocial Support in Older Patients With Metastatic Breast Cancer (MBC) Treated at Community Centers Journal of the National Comprehensive Cancer Network. 18 |
| Khan SA, Zhao F, Solin LJ, et al. (2020) A randomized phase III trial of systemic therapy plus early local therapy versus systemic therapy alone in women with de novo stage IV breast cancer: A trial of the ECOG-ACRIN Research Group (E2108). Journal of Clinical Oncology. 38 |
| Varshavsky-Yanovsky AN, Goldstein LJ. (2019) Role of Capecitabine in Early Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 38: 179-182 |
| Goetz MP, Gradishar WJ, Anderson BO, et al. (2019) NCCN Guidelines Insights: Breast Cancer, Version 3.2018. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 118-126 |
| Blackwell KL, Zaman K, Qin S, et al. (2019) Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2-positive Breast Cancer: A Phase I/II Study. Clinical Breast Cancer. 19: 97-104.e4 |
| Bleicher RJ, Chang C, Wang CE, et al. (2018) Treatment delays from transfers of care and their impact on breast cancer quality measures. Breast Cancer Research and Treatment |